关注的可能改变临床实践的研究
NCT 02468024 (STABLE-MATES) A Randomized Phase III Study of Sub-lobar Resection Versus Stereotactic Ablative Radiotherapy in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial. Primary outcome measure is overall survival. Estimated enrollment is 272 patients.
NCT 02984761 (VALOR) Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy Trial. Primary outcome measure is overall survival. Estimated enrollment is 670 patients.
NCT 02194738 (ALCHEMIST) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial. Primary outcome measures are central genotyping and feasibility of research grade tissue collection. Estimated enrollment is 8300 patients.
NCT 02193282 (An ALCHEMIST Treatment Trial) Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC). Primary outcome measure is overall survival. Estimated enrollment is 450 patients.
NCT 02201992 (An ALCHEMIST Treatment Trial) A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. Primary outcome measure is overall survival. Estimated enrollment is 378 patients.
NCT 02595944 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers. Primary outcome measures are overall survival and disease-free survival. Estimated enrollment is 714 patients.
NCT 01993810 (RTOG 1308) Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC. Primary outcome measure is overall survival. Estimated enrollment is 330 patients.
NCT 02525757 DETERRED: PD-L1 blockade To Evaluate the Safety of Lung Cancer Therapy Using Carboplatin, Paclitaxel, and Radiation Combined with MPDL3280A. Primary outcome measure is time to toxicity. Estimated enrollment is 52 patients.
NCT 03391869 (LONESTAR) Randomized Phase III Trial of Local Consolidation Therapy After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients with Metastatic Non-Small Cell Lung Cancer -Strategic Alliance: BMS. Primary outcome measure is overall survival. Estimated enrollment is 270 patients.
NCT 03137771 Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial. Primary outcome measures are progression-free survival (phase 2) and overall survival (phase 3). Estimated enrollment is 300 patients. |
